Clinical Case Webinars

NSW Clinical Guidelines: Treatment of
Opioid Dependence

• • • • • • Benzodiazepine use – illicit and prescribed
          • Assessment for people with benzodiazepine use
          • Strategies for benzodiazepine management (Table 25)
          • Situations that influence treatment planning (polydrug use, chronic pain)
          • Chronic and acute pain management
          • Key drug interactions (Table 27)
          • Other drug interactions
          • Responding to continued substance use
          •  Assessments for people on opioid agonist treatment

Hard copies of the guidelines can be requested from:
moh-populationhealthresources@health.nsw.gov.au

---

In this session, we discuss key the challenges you may come across when transferring a patient to buprenorphine pharmacotherapies for treating opioid dependence, including highlighting the potential role for microdosing transfers. What are the options for buprenorphine transfers and initiation? What factors can complicate initiation onto buprenorphine and how do we manage them?

Leading this session was Dr Chris Tremonti, Addiction Specialist and Clinical Pharmacologist at St Vincent’s Drug and Alcohol Services. Joining in the conversation included over 75 attendees for this session, alongside Dr Sharon Reid, Medical Officer & OTAC Clinical Academic Advisor, and Mr Daniel Winter, OTAC Coordinator, both from the University of Sydney Specialty of Addiction Medicine & Drug Health Services, Sydney Local Health District.Webinar Resources

Webinar Resources

---

Download presentation slides (PDF)

 

 

 

 

---

NSW Clinical Guidelines: Treatment of
Opioid Dependence

• • Appropriate doses for OAT initiation
  • Drug interactions with OAT
  • COWS Assessment
  • SOWS Assessment
  • Transfer to methadone – When transferring from buprenorphine to methadone
  • Transfer to buprenorphine – Transferring to buprenorphine from methadone or sustained-release pharmaceutical opioids

Hard copies of the guidelines can be requested from:
moh-populationhealthresources@health.nsw.gov.au

---

Clinical Guidelines for depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence

• • Commencing depot BPN treatment

This webinar topic was on switching between & within OAT pharmacotherapies, facilitated by: Dr Joshua Watt, Dr Sharon Reid, Mr Daniel Winter, of the Specialty of Addiction Medicine, University of Sydney & Sydney Local Health District Drug Health Services. This session was recorded on Tuesday 22nd November 2022.

In this webinar, we discuss what clinicians should consider when transferring a patient between methadone, sublingual buprenorphine or depot buprenorphine pharmacotherapies. Within the discussion we reflect upon clinical considerations that may impact on medication choice, including common pitfalls, patient preference, and patients who may be pregnant.

This webinar topic was on OAT takeaway connundrums, facilitated by: Prof Paul Haber, Dr Sharon Reid, Mr Daniel Winter of the Specialty of Addiction Medicine, University of Sydney & Sydney Local Health District Drug Health Services. This session was recorded on Tuesday 6th September 2022.

In this webinar, we discuss the clinical conundrums to consider around providing takeaways to a patient on OAT. What are the risks and benefits of providing takeaways? What should you do if you need to consider going outside the guidance for takeaways? We also ask the audience what their experiences have been in providing takeaways to patients, or what challenges that they have faced in their clinical practice.

---